Ca-DTPA Articles
US FDA calls on pharma for anti-radiation NDAs
22 September 2003
Showing 1-1 of 1 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
